SOURCES SOUGHT
A -- NIMH Psychoactive Drug Screening Program (PDSP) - Draft SOW
- Notice Date
- 7/19/2017
- Notice Type
- Sources Sought
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Mental Health, Contracts Management Branch, 6001 Executive Blvd, Rm 8154, MSC 9661, Bethesda, Maryland, 20892-9661
- ZIP Code
- 20892-9661
- Solicitation Number
- HHS-NIH-NIDA-(MH)-RDSS-17-012
- Point of Contact
- Rosanne S. W. Ogoh, Phone: 301-443-4433, Stephanie D. Dewitt, Phone: 3014434116
- E-Mail Address
-
ogohr@mail.nih.gov, stephanie.dewitt@nih.gov
(ogohr@mail.nih.gov, stephanie.dewitt@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- DRAFT SOW This is a Research and Development (R&D) Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential R&D requirement. Small Businesses are encouraged to respond. BACKGROUND The mission of the National Institute of Mental Health (NIMH) is to transform the understanding and treatment of mental illnesses through basic and clinical research, paving the way for prevention, recovery, and cure. Specifically, for this requirement, the goal is to support fundamental research on the mechanisms underlying and influencing brain development, neuronal signaling, synaptic plasticity, signal transduction pathways, and the biochemical and behavioral actions of therapeutic agents in animals and humans. The goals include the identification of novel targets (genes or molecules) for therapeutic intervention, characterization of the neurobiological behavioral actions of psychoactive agents, and design and development of novel ligands for functional brain imaging in humans, psychoactive agents for basic and clinical research, and potential therapeutic agents for the treatment of mental disorders. To further these goals, a requirement for the NIMH Psychoactive Drug Screening Program (PDSP) was initiated to provide broad-based screening capabilities, in the form of pharmacological and functional assays, and receptor binding data (Ki values) to the scientific research community with the intent of stimulating innovative research and development efforts in the design and development of novel psychoactive compounds for preclinical research, neuroimaging, and as potential therapeutic agents in the treatment of psychiatric disorders. The program focuses on the use of state-of-the-art, high-throughput screening (HTS) of compounds in human and rodent central nervous system (CNS) binding and functional assays. PURPOSE AND OBJECTIVES: The purpose of the NIMH PDSP is to provide screening of novel synthetic compounds and natural products for potential use as research tools or probes for basic and clinical research, as therapeutic agents for mental disorders, and as PET, SPECT, and fMRI ligands for functional brain imaging. This program is primarily intended as a screen for compounds that have previously been shown to possess pharmacological, biochemical, or behavioral activities relevant to NIMH and not for the purpose of large-scale, random screening of natural products or combinatorial libraries (e.g., libraries containing >1000 compounds). However, screening maybe conducted on small libraries of synthetic or natural product compounds of unknown activity and on hit or lead compounds generated through NIH-funded HTS or chemistry programs. Compounds will be provided by the research community, primarily NIH-supported investigators. It is anticipated that the Contractor will receive and screen compounds on a `continuous and on-going basis, although the volume of requests will vary from month to month. The objectives of the requirement are to receive and test approximately 4,000-5,000 samples (e.g., small molecules, gene products, and natural product extracts) per year, as specified by SOW, in broad-based human and rodent CNS screening assays, and to provide an electronic data file for each of the screened compounds. Samples for screening can include, but are not limited to, novel chemical entities, structural analogs of lead compounds, genes or gene products, and natural products. It is anticipated that NIMH-approved and coded samples will be submitted in individual vials or in a plated format from NIH-funded research programs, academic research programs, or other sources. It is expected that the screening information derived from this program will provide individual investigators with data addressing the specificity and/or activity of compounds at CNS targets. The annual assay workload is estimated as follows: • 35,000 primary pharmacologic assays • 7,500 secondary pharmacologic assays • 125,000 functional assays • 1,250 ADMET assays • 5 new assays developed and validated As demand for contract services may vary, the Contractor shall maintain the capability of expanding throughput to meet a higher assay volume. The requirement will contain options for increased quantities that may be exercised multiple times within a performance period to fund a higher volume of screening. In addition, an option for fee-for-service may be included to provide screening at no cost to requesting investigators. The contractor shall have the ability to conduct screening on a fee-for-service basis, if requested by the government. Prices for the services provided shall be set based on full or partial recover of actual costs. PROJECT REQUIREMENTS: The Contractor is expected to 1) Provide an outline/overview of the Sample Screening Process; 2) Obtain required Assurances and Project Protocols; 3) Process Requests and Sample Receipt, Storage, and Confidentiality; 4) Screen Assays; 5) Incorporate Novel Techniques and Technologies; 6) Develop and maintain two databases (i.e. Data Management and PDSP Ki Databases) that are 508 compliant; and 7) Provide Outreach and Communication REPORTS/DELIVERABLES: The Contractor is expected to provide 1) Assay Reports within one week of completion of testing; 2) Quarterly Reports within seven (7) calendar days after the end of each contract quarter; 3) Annual Reports within fourteen (14) calendar days after the expiration of each contract performance period; 4) Final Report on or before the contract expiration date; and 5) a Transition Plan - Transition to a subsequent Contractor or to the Government upon request at any time within the contract performance period. ANTICIPATED PERIOD OF PERFORMANCE: The anticipated period of performance is one 12-month base period and four 12-month option periods from 08/30/2018 through 08/29/2023. Additionally, the option for increased quantities is expected to be exercised within the contract period of performance. OTHER IMPORTANT CONSIDERATIONS: The Government is expected to use procedures in FAR Part 15, Contracting by Negotiations. It is anticipated that a Level of Effort, Cost Reimbursement type contract will be issued. The North American Industry Classification System (NAICS) Code 541711 with a size standard of 1,000 employees is being contemplated. CAPABILITY STATEMENT/INFORMATION SOUGHT: a. Capability Statement - Respondents to this notice must provide, as part of their responses, a capability statement to include the following: (1) information regarding the respondents' (a) staff expertise, including their availability, experience, and formal and other training; (b) current in-house capability and capacity to perform the work; (c) prior completed projects of similar nature; (d) corporate experience and management capability; and, (e) examples of prior completed Government contracts, references, and other related information; (2) respondents' DUNS number, organization name, address, point of contact, and size and type of business (e.g., 8(a), HUBZone, etc.) pursuant to the applicable NAICS code; (3) any catalog prices for the services described above; and (4) any other information that may be helpful in developing or finalizing the acquisition requirement. b. Information Submission Instructions - Respondents should provide responses accordingly: (1) submit information both electronically and by mail. No telephone or facsimile responses will be accepted; (2) format capability statements using Microsoft Word or Adobe PDF including attachments, resumes, charts, etc. Use single space, 12 font minimum and 8 ½ x 11 size paper; (3) organize material in such a manner that clearly identifies and addresses capability requirements and provide an executive summary; (4) capability statement should not exceed ten (10) single sided pages including references; (5) respondents must send two original copies via mail and one electronic copy via email; (6) responses should be received no later than August 3, 2017 at 4:00 PM Local Time; (7) include respondents' technical and administrative points of contact, including names, titles, addresses, telephone and fax numbers, and e-mail addresses; and (8) send responses to this notice via email to ogohr@mail.nih.gov. The original statements mailed using the U.S. Postal Service should be sent to ATTN: Rosanne Ogoh, National Institutes of Health, Office of Acquisitions - NIDA Neuroscience COAC, NIMH R&D Contracts Management Section, 6001 Executive Boulevard, Room 8154, MSC 9661, Bethesda, MD 20892-9661. If using a courier service such as the UPS, Federal Express, etc., change the City, State and Zip Code to Rockville, MD 20852. (Please be aware that the U.S. Postal Service's "Express Mail" DOES NOT deliver to the Rockville, Maryland address.) DISCLAIMER AND IMPORTANT NOTES. This notice does not obligate the Government to award a contract or otherwise pay for the information provided in response. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Any organization responding to this notice should ensure that its response is complete and sufficiently detailed to allow the Government to determine the organization's qualifications to perform the work. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback to respondents with respect to any information submitted. After a review of the responses received, a pre-solicitation synopsis and solicitation may be published in Federal Business Opportunities. However, responses to this notice will not be considered adequate responses to a solicitation. CONFIDENTIALITY. No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s).
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIMH/HHS-NIH-NIDA-(MH)-RDSS-17-012/listing.html)
- Record
- SN04585864-W 20170721/170719234915-d26adc3a6d89adfbba478de065a4851e (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |